Lower starting dose of roxadustat in non-dialysis-dependent chronic kidney disease patients with anaemia: a study protocol for a randomised, multicentre, open-label study

INTRODUCTION: Roxadustat is a first-in-class oral therapy that treats chronic kidney disease (CKD) anaemia with the benefit of a novel mechanism of action that consistently corrects and maintains haemoglobin (Hb) across the spectrum of non-dialysis-dependent (NDD) CKD anaemia with an acceptable safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ping, Sun, Xuefeng, Chen, Dinghua, Lin, Hong-li, Zhang, Li, Wu, Yiqing, Pan, Shuting, Cai, Guangyan, Chen, Xiangmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Renal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923260/
https://www.ncbi.nlm.nih.gov/pubmed/36759031
http://dx.doi.org/10.1136/bmjopen-2022-068864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923260/
https://www.ncbi.nlm.nih.gov/pubmed/36759031
http://dx.doi.org/10.1136/bmjopen-2022-068864

Ejemplares similares